Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with Rosiglitazone

Table 1

Clinical characteristics of the study subjects at baseline.

	Placebo group	RSG group	𝑃
𝑁	31	30
Age	59.4±8.6	58.4±10.0	0.668
Female (%)	58.1%	56.7%	1.000
Body weight (kg)	65.7±9.0	65.9±11.5	0.943
Body length (m)	1.59±0.08	1.59±0.09	0.932
BMI (kg/m^2)	26.0±3.2	25.9±2.9	0.868
Systolic blood pressure, mmHg	136±17	128±14	0.037
Diastolic blood pressure, mmHg	81±10	80±9	0.053
HbA1c, (%)	9.92±1.66	9.74±1.36	0.646
Fasting plasma glucose, mmol/L	11.14±3.00	10.95±2.72	0.801
Fasting plasma insulin, pmol/L	94.55±53.92	82.03±42.23	0.391
Total cholesterol, mmol/L	5.80±1.12	5.28±0.92	0.055
Total triglyceride, mmol/L	2.42±1.85	2.15±1.25	0.583
LDLc, mmol/L	3.53±1.22	3.13±0.83	0.134
HDLc, mmol/L	1.15±0.29	1.22±0.42	0.450
HOMA2-%S	66.37±41.49	66.70±37.75	0.383
HOMA2-%B	41.52±36.27	36.81±39.01	0.631
HOMA-IR	6.28±3.30	5.50±3.18	0.368
HOMA-𝛽	49.36±50.09	43.53±65.45	0.502
ALS, mU/mL	1284.9±459.4	1474.9±842.8	0.854

Each value represents the mean ± standard deviation. The 𝑃 value is derived from a Student’s 𝑡-test. RSG: rosiglitazone; BMI: body mass index; HbA1c: hemoglobin A1c; LDLc: low-density lipoprotein cholesterol; HDLc: high-density lipoprotein cholesterol; HOMA2-%S: homeostatic model assessment version 2 insulin sensitivity; HOMA2-%B: homeostatic model assessment version 2 𝛽-cell function; HOMA-IR: homeostatic model assessment of insulin resistance; HOMA-𝛽: homeostatic model assessment of 𝛽-cell function; ALS: acid-labile subunit.